Search Results 491-500 of 14818 for anti-TNF drugs

1. Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) - Mayo Clinic

   Treatment with an anti-complement therapy or with Zileuton (Zyflo) within the last three months prior to baseline (Day 1). OCS dose no more than 0.3mg/kg ...

2. Triamterene And Hydrochlorothiazide (Oral Route) Before Using - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

3. Tbo-Filgrastim (Subcutaneous Route) Description and Brand Names - Mayo Clinic

   When certain cancer medicines are used to fight cancer cells, they also affect the white blood cells that fight infections. Tbo-filgrastim is used to ...

4. Anabolic Steroid (Oral Route, Parenteral Route) Side Effects - Mayo Clinic

   Tumors of the liver, liver cancer, or peliosis hepatis, a form of liver disease, have occurred during long-term, high-dose therapy with anabolic steroids.

5. New treatment option for early type 1 diabetes - Mayo Clinic

   According to findings published in The New England Journal of Medicine in 2023, teplizumab is an anti-CD3 antibody approved for people 8 years and older ...

6. Calcipotriene (Topical Route) Description and Brand Names - Mayo Clinic

   Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Calcitrene; Dovonex; Sorilux. Descriptions.

7. Tuberculin (Intradermal Route) Description and Brand Names - Mayo Clinic

   Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Aplisol; Tubersol. Descriptions. Tuberculin ...

8. Mayo Clinic researchers identify cancer-fighting drugs that help morbidly obese mice to lose weight

   17 edition of Oncotarget. “We were surprised to observe that when morbidly obese mice were treated with certain cancer-fighting drugs, the drugs not only ...

9. Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218) - Mayo Clinic

   Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or ...

10. Tobramycin And Dexamethasone (Ophthalmic Route) Description and Brand Names - Mayo Clinic

    Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Tobradex; Tobradex ST. Canadian Brand Name.